MiNK Therapeutics Inc (NASDAQ:INKT) Reports Wider Q2 2025 Loss, Advances Clinical Pipeline Amid Market Caution

MiNK Therapeutics Inc (NASDAQ:INKT) reported its second-quarter 2025 financial results, missing analyst expectations on earnings per share (EPS) while maintaining no revenue, as anticipated. The clinical-stage biopharmaceutical company posted a net loss of $4.2 million, or $1.06 per share, compared to analyst estimates of a $0.56 loss per share. Revenue for the quarter remained at $0.0, in line with expectations.

Key Financial Takeaways

• EPS Miss: Reported a net loss of $1.06 per share, nearly double the estimated loss of $0.56.
• No Revenue: As expected, the company generated no revenue, consistent with its clinical-stage status.
• Cash Position: Ended Q2 with $1.6 million in cash and equivalents, later bolstered by a $13 million equity raise, extending the cash runway into mid-2026.
• Cash Burn Reduction: Cash used in operations declined 31% year-over-year to $1.6 million, reflecting cost management efforts.

Market Reaction

Following the earnings release, the stock has seen mixed performance:

• Short-term: The stock is down approximately 9.5% since the earnings announcement.
• Recent Week: A slight rebound of 0.34% suggests some stabilization after initial selling pressure.
• One-Month Trend: Shares remain down 24.3%, reflecting broader investor caution around the wider-than-expected loss.

The market’s negative reaction appears tied to the larger-than-anticipated loss, despite the company’s progress in clinical programs and non-dilutive funding achievements.

Clinical and Strategic Highlights

Beyond financials, MiNK Therapeutics highlighted several key developments:

• Durable Complete Remission in Metastatic Testicular Cancer: A case study published in Nature’s Oncogene showcased a patient achieving long-term remission after treatment with agenT-797 (iNKT cell therapy) combined with checkpoint inhibitors.
• Grants for GvHD Programs: The company secured two non-dilutive grants, including a Department of Defense STTR grant, to advance iNKT cell therapies for graft-versus-host disease (GvHD). A clinical trial is expected to begin in the second half of 2025.
• Phase 2 Gastric Cancer Study: Additional data readouts are anticipated later this year.
• Peer-Reviewed Validation: A review in Frontiers in Immunology highlighted the potential of iNKT cell therapies in overcoming tumor resistance.

Outlook vs. Analyst Estimates

While the company did not provide explicit financial guidance, analysts project:

• Q3 2025: Estimated EPS of -$0.55 with no revenue expected.
• Full-Year 2025: Estimated EPS of -$2.01, also with no revenue forecasted.

The lack of revenue expectations is typical for a pre-commercial biotech firm, but the widening losses may continue to weigh on investor sentiment until clinical milestones translate into partnerships or accelerated development.

Conclusion

MiNK Therapeutics’ Q2 results reflect the challenges of a clinical-stage biotech balancing clinical progress with financial sustainability. While the EPS miss has pressured the stock, the company’s strengthened cash position and advancing pipeline—particularly in GvHD and oncology—could provide catalysts in the coming quarters.

For more detailed earnings and estimates, visit MiNK Therapeutics’ earnings page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research before making any financial decisions.